At first glance a strategically brilliant move by Imugene to...

At first glance a strategically brilliant move by Imugene to return $32 million USD to the balance sheet in the ensuing years, negating the need for further capital raises in 2024 and extending the cashflow runway out to 2026. More importantly enabling the company to "stick to their knitting" and focus on their core operations, those being to develop novel cancer therapies such as Azer Cel, Vaxinia, PD1 Vaxx and Oncarlytics.

Yesterdays announcement Imugene has commenced the bile duct expansion in their Vaxinia Trial and todays announcement they have a professional team to manufacture and deliver Azer Cel product brings us closer to the prospect of Registration Trials for both drugs. Revenue may now be closer than many had anticipated this time last year, when the stock was actually trading at higher multiples that it is now, at 14 cents.

DYOR Seek investment advice as and when required opinions only